
Gastroschisis



Disclaimer: This clinical pathway is provided as a general guideline for use by Licensed Independent Provider's (LIP) in planning care and treatment of patients. It is not intended to be and does not establish a standard of care. Each patient's care is individualized according to specific needs.



Infants with Gastroschisis are at high risk for

- Late onset sepsis (PATHWAY LINK)
- Skin and soft tissue infections (cellulitis, abscess, post-wound debridement etc.)
- Central line associated bacterial infections
- UTI and pneumonia (mainly for those who remain intubated)
- Small Intestinal Bacterial Overgrowth (SIBO)

Intestinal Atresia



Gastroschisis Pathway

Pre-Procedure Prophylaxis Pathway



Small Bowel Atresia Delivery Room Management

- Cautious/judicious use of prolonged CPAP or NIMV
- Place replogle to low intermittent suction
- PIV if infant on minimal respiratory support
- Consider umbilical lines for:
 - Intubated infants
 - Inability to obtain PIV
 - Central access is needed for other reasons
- PICC will be placed at ACH

IV Fluids

- Total fluids at least 80 ml/kg/day
- Consider NS bolus 10 ml/kg

Labs

- Blood gas
- Hematocrit
- BMP
- Newborn screen
- Blood culture, if clinically indicated

Imaging


• 2 view abdominal x-ray

Consult

Surgery consult

Pre-Procedure Antibiotics





Surgical Prophylaxis:

- Cefazolin 25 mg/kg every 12 hours (or every 8 hours for infants > 7 days)
 - Cefazolin to be given within 60 minutes of surgical start time

Peri-operative:

Antibiotics not recommended in the absence of culture positive sepsis or clinical instability in small bowel atresia or uncomplicated gastroschisis (perforation, vascular compromise) for:

- Staged closure with silo
- Suture-less closure at bedside

Post-operative:

Recommend discontinuation of antibiotic therapy 24 hours after abdominal closure/surgery in the absence of culture-positive sepsis or clinical instability.

Metrics



Contributing Members



Ankita Shukla, MD – Neonatology
Ashley Ross, MD – Neonatology
Franscesca Miquel Verges, MD – Neonatology
Steve Dahl, MD – Infectious Disease
Jessica Snowden, MD – Infectious Disease
Caleb McMinn, PharmD – Inpatient Pharmacy
Phillip Rampey, PharmD – NICU Pharmacy
Holly Maples, PharmD – Director, Antimicrobial Stewardship
Abdallah Dalabih, MD – Medical Director, Clinical Effectiveness & Outcomes
Emily Rader, MSN, Clinical Effectiveness & Outcomes Manager
Sophia Blythe, MHA, Clinical Effectiveness & Outcomes Project Coordinator

References



Children's Hospital of Orange County (CHOC). 2018. Gastroschisis Clinical Guideline. https://www.choc.org/wp/wp-content/uploads/2018/06/GastroschisisClinicalGuideline.pdf